All information contained in this document is intended to be used at the discretion of each individual center to help guide quality and safety program improvement. There are no legal standards
supporting this document; specific federal or provincial regulations and licence conditions take precedence over the content of this document.
| SYSTEM DE SCRIPTION
Brachytherapy is the placement of encapsulated radionuclides or a miniaturized x-ray tube in, or adjacent to, tissue which has been prescribed a radiation dose. [3] [4] [5] [6] [7] [8] [9] [10] This practice offers unique advantages to the management of several treatment sites and has been used to complement or replace external beam radiation therapy since the onset of radiation oncology.
Remote afterloading equipment was developed to reduce, and in many cases eliminate, the radiation exposure to members of the staff.
With remote afterloading systems the user does not directly handle the radioactive source and the patient is irradiated in a shielded room with staff operating and monitoring the process remotely.
High dose rate (HDR) refers to treatment dose rates larger than 20 cGy/min. For all HDR remote afterloaders, a single and small (< 1 mm 9 5 mm) radioactive source (mostly iridium-192, rarely cobalt60), laser-welded to a metallic cable, is moved out of the safe by a motor-drive mechanism to step along the prescribed positions High-dose rate miniaturized x-ray tube remote devices, along with intravascular and cardiovascular brachytherapy remote afterloaders using beta emitting radioactive sources, are beyond the scope of this document.
Various recommendations for brachytherapy quality assurance have been reported in the literature. [11] [12] [13] [14] [15] [16] [17] [18] "Per treatment" tests must be executed prior to each treatment. "Treatment day" tests must be scheduled before treating the first patient of the day. For
PDR remote afterloaders where treatments may last several days,
"treatment day" tests should be performed prior to the initiation of the treatment. 
| RELATED TECHNICAL QUALITY CONTROL GUIDELINE S

Q2
The configuration of this test will depend on the design of the facility and equipment. Safety is the concern and tests should be designed accordingly. The first objective is to verify that the equipment safely retracts the source wire after a power failure. The second objective is to verify that the equipment properly records treatment delivered before power failure and permits to resume the treatment after power recovery Q3 
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